Approved for Use in Europe to Identify Head and Neck Cancer Patients Most Likely to Benefit from Opdivo (nivolumab) Therapy
SANTA CLARA, Calif., May 15, 2017
Agilent Technologies Inc. (NYSE: A) today announced the expanded use of Agilent’s Dako PD-L1 IHC 28-8 pharmDx test for squamous cell carcinoma of the head and neck (SCCHN), the most prevalent type of head and neck cancer.
Europe is the first region to launch a PD-L1 CE-IVD test for SCCHN globally. The CE marking demonstrates that the product meets all relevant European Medical Device Directives. The PD-L1 IHC 28-8 pharmDx test has broad utility, as it has already been previously CE marked
for tumor cell PD-L1 expression for non-squamous, non-small-cell lung cancer (ns-NSCLC)
and melanoma.
With this latest indication, pathologists in Europe now have access to a clinically validated test to determine tumor PD-L1 status PD-L1, in patients with SCCHN. There are currently few treatment options for SCCHN, but this new test can identify which patients could most likely benefit from treatment with Opdivo (nivolumab), an immunotherapy developed by Bristol-Myers Squibb. Opdivo as monotherapy is indicated for the treatment of squamous cell cancer of the head and neck in adults progressing on, or after platinum-based therapy.
Data from a pre-specified exploratory analysis of the Checkmate 141 clinical trial showed that tumor PD-L1 expression, as detected by PD-L1 IHC 28-8 pharmDx in SCCHN, may be associated with an enhanced survival benefit for the patient from the use of Opdivo.
Immunotherapies are designed to help an individual’s immune system detect and kill cancer cells. Because individual patients often respond differently to the same treatment, scientists have been focusing emphasis on personalized medicine, which is where Agilent’s Dako brand of diagnostics comes into play, providing important information about the status of key biomarkers in individual cancer patients.
“It is encouraging to see new indications validated both analytically and clinically, for the PD-L1 28-8 assay,” said Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group, which includes Dako, a provider of pathology solutions that Agilent acquired in 2012. “We recently saw the first approval for the PD-L1 IHC 28-8 pharmDx test, in head and neck cancer in Japan, and are now pleased that the CE marked indication has been extended to Europe. Head and neck cancer has few treatment options, and tumor PD-L1 testing can identify patients with this devastating disease who are most likely to benefit from Opdivo therapy.”
PD-L1 IHC 28-8 pharmDx is the first and only diagnostic assay approved to assess the survival benefit with Opdivo in patients with SCCHN and was developed in collaboration with Bristol-Myers Squibb.
Agilent is a worldwide leader in partnering with pharmaceutical companies to develop immunohistochemical-based diagnostics for cancer therapy.
Expanded use in other countries is currently pending approval.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide.
In 2012, Agilent acquired Dako, a well-known provider of reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients.
Information about Agilent is available here, and information about Dako is available here.
# # #
Contact:
Victoria Wadsworth-Hansen
Agilent Technologies
+1 408-553-2005
+45 29 33 69 80
victoria.wadsworth-hansen@agilent.com
| http://www.agilent.com/about/newsroom/presrel/2017/15may-ca17014.html |